Advantages of Metformin Therapy for Diabetic Foot Ulcer Prevention and Mitigation
Main Article Content
Abstract
Introduction: Diabetes foot is one of the most common complications of diabetes. Metformin treatment may aid in lowering the prevalence of diabetic foot ulcers in diabetic patients.
Study objectives: The purpose of this study was to look into the prevalence of diabetic foot ulcers among diabetic patients attending out-patient, as well as the impact of metformin treatment on the development of diabetic foot ulcers.
Methodology: To collect data from diabetic patients' files, a retrospective design was used. Demographic variables such as gender and age were included in the study, as well as clinical variables such as diabetes duration, metformin treatment, and diabetic foot ulcer status. Data was gathered and entered into SPSS version 20 for analysis. Descriptive features of statistical analysis included frequency, percentage, mean, and standard deviation. Various statistical models, such as the Chi-square test, One Way Anova, and Pearson's correlation, were used to investigate the relationship between variables. If p 0.05, the significance was accepted.
Results: The study included 62 diabetic patients with an average age of 56.9511.98 years. The males were 33 (53.2%), the duration of diabetes was 7.55.86 years, metformin was prescribed to approximately 66% of patients, the mean metformin dose was 1617.32649.49 mg, and the prevalence of DF was 8.1%. There were no significant relationships between DF and gender or metformin use (p>0.05). Both the One-Way Anova Test and the correlation test revealed that DF was significantly related to DF.
Conclusion: The current study found that metformin treatment is significantly associated with metformin dose and could protect diabetic patients from developing DF.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Park J, Peters PA. Mortality from diabetes mellitus, 2004 to 2008: A multiple-cause-of-
II. death analysis. Health Rep., 2014, 25(3):12–6.
III. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract.,2014, 103(2):137–49.
IV. Lee WJ, Song KH, Noh JH, Choi YJ, Jo MW. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes. J Korean Med Sci., 2012, 27(3):255–60.
V. Rodriguez BolanosRde L, ReynalesShigematsu LM, Jimenez Ruiz JA, Juarez Marquezy SA, Hernandez Avila M. Direct costs of medical care for patients with type 2 diabetes mellitus in Mexico micro- costing analysis. Rev PanamSaludPublica., 2010, 28(6):412–20.
VI. O'Reilly DJ, Xie F, Pullenayegum E, Gerstein HC, Greb J, Blackhouse GK, et al. Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Metformin and Wound Healing in Diabetic Foot Ulcers. Life Res., 2011, 20(6):939–43.
VII. Castro-Rios A, Nevarez-Sida A, Tiro- Sanchez MT, Wacher-Rodarte N. Triggering factors of primary care costs in the years following type 2 diabetes diagnosis in Mexico. Arch Med Res.,2014, 45(5):400– 8.
VIII. Ng CS, Lee JY, Toh MP, Ko Y. Cost-of- illness studies of diabetes mellitus: a systematic review. Diabetes Res ClinPract., 2014, 105(2):151–63.
IX. Margolis DJ, Jeffcoate W. Epidemiology of foot ulceration and amputation: can global variation be explained? Med Clin North Am.2013, 97(5):791–805.
X. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA.2005, 293 (2):217–28.
XI. Murphie P. Macrovascular disease aetiology and diabetic foot ulceration. J Wound Care, 2001, 10 (4):103-107.
XII. Krishnan STM, Baker NR, Carrington AL, Raymann G. Comparative roles of microvascular and nerve function in foot ulceration in type 2 diabetes. Diabetes Care, 2004, 27(6):1343-1348.
XIII. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Swerzgold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes, 1999, 48(1): 198-202.
XIV. Kirpichnikov D, McFarlane SI, Sowers JR Metformin: an update. Ann Intern Med, 2002, 137 (1):25-33.
XV. De Jager J, Kooy A, Lehert P, et al . Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomised, placebo-controlled trial. J Intern Med, 2005, 257(1):100-109.
XVI. Marre M. Before oral agents fail: the case for starting insulin early. Int J ObesRelatMetabDisord., 2002, 26(3):25-30.
XVII. Avile´s-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med., 1999, 131(3):182-188.
XVIII. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med., 1999, 130 (5):389-396.
XIX. Wulffele´ MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care., 2002, 25(12):2133-2140.